Quick Answer
KALA BIO, Inc. reported Net Income Loss of -$38.51 million for the year ending 2024.
- KALA BIO, Inc. showed an increase of +8.7% in Net Income Loss from 2023 to 2024.
- This data is from KALA BIO, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2025.
- XBRL data for this metric is available from 2015 to 2024 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$11.30 million | Q2 2018: -$14.62 million | Q3 2018: -$15.60 million | Q1 2019: -$25.39 million | Q2 2019: -$23.83 million | Q3 2019: -$23.18 million | Q1 2020: -$21.96 million | Q2 2020: -$23.31 million | Q3 2020: -$27.95 million | Q1 2021: -$30.41 million | Q2 2021: -$36.50 million | Q3 2021: -$28.13 million | Q1 2022: -$32.94 million | Q2 2022: -$28.11 million | Q3 2022: $29.07 million | Q1 2023: -$14.46 million | Q2 2023: -$10.41 million | Q3 2023: -$8.70 million | Q1 2024: -$11.81 million | Q2 2024: -$9.58 million | Q3 2024: -$8.95 million | Q1 2025: -$8.95 million | Q2 2025: -$11.16 million | Q3 2025: -$7.56 million.
- Over the full 10 years of available data (2015 to 2024), KALA BIO, Inc.'s Net Income Loss has declined by 130.9%.
- Historical annual values: Fiscal year 2024: -$38.51 million | Fiscal year 2023: -$42.20 million | Fiscal year 2022: -$44.82 million | Fiscal year 2021: -$142.61 million | Fiscal year 2020: -$104.33 million | Fiscal year 2019: -$94.35 million | Fiscal year 2018: -$66.74 million | Fiscal year 2017: -$42.21 million | Fiscal year 2016: -$33.17 million | Fiscal year 2015: -$16.68 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: